What is The Worth of Gene Therapy w/ ICER President & CEO, Sarah K. Emond, MPP | HealthBiz Briefs
Sarah Emond (President and CEO, ICER) delves into the efficacy of gene therapy in enhancing patient outcomes and discusses the necessary adjustments the healthcare industry must make to accommodate the cost.
🎙️⚕️ABOUT CARETALK
CareTalk is a weekly podcast that provides an incisive, no B.S. view of the US healthcare industry. Join co-hosts John Driscoll (Senior Advisor, Walgreens Health) and David Williams (President, Health Business Group) as they debate the latest in US healthcare news, business and policy.
🎙️⚕️ABOUT SARAH K. EMOND, MPP
With 25 years of experience in the business and policy of health care, Sarah leads the Institute for Clinical and Economic Review, a leading non-profit health policy research organization, as President and Chief Executive Officer. She joined ICER in 2009 as its first Chief Operating Officer and third employee, and has worked to grow the organization’s approach, scope, and impact over the years.
Prior to joining ICER, Sarah spent time as a communications consultant, with six years in the corporate communications and investor relations department at a commercial-stage biopharmaceutical company, and several years with a healthcare communications firm. Sarah began her healthcare career in clinical research at Beth Israel Deaconess Medical Center in Boston.
A graduate of the Heller School for Social Policy and Management at Brandeis University, Sarah holds a Master of Public Policy degree with a concentration in health policy.
GET IN TOUCH
Become a CareTalk sponsor
Guest appearance requests
Visit us on the web
Subscribe to the CareTalk Newsletter
Shop official CareTalk merch
FOLLOW CARETALK
Spotify
Apple Podcasts
Google Podcasts
Follow us on LinkedIn
#healthcare #healthcaretechnology #healthcarebusiness #healthcarepodcast #genetherapy #medicaladvancements
CareTalk: Healthcare. Unfiltered. is produced by Grippi Media Digital Marketing
